Features
Latest World Pharmaceuticals Feature
Without lipid nanoparticles, there’s no mRNA vaccine, no 95% efficacy,...
> read more
Root and branch Pharmaceutical companies were setting ambitious deadlines for improving supply chain sustainability prior to Covid-19. The pandemic has since laid bare their reliance on complex chains...
War and IPs Like never before, the pharmaceutical supply chain is a geopolitical arena, but when every surge of the virus and variation in vaccine yield raises the stakes, familiar...
Pathway to excipients Innovation in drug development has continued at an often dizzying pace during the pandemic, but in the area of excipients, it’s hampered by a burdensome regulatory process. Kim...
Track and trace There’s nothing like a pandemic for demonstrating the necessity for serialisation, interoperability, and more advanced analytics and tracking. Tim Gunn asks Rob Handfield, the...
Close of play Given the lack of standardisation on shape, size and material for closed-system transfer devices (CSTDs), many pharmaceutical companies are struggling to ensure their products work...
4.0 lights the way It might sound like the latest software update for your iPhone, but Industry 4.0 is sending shockwaves through manufacturing industries. Mae Losasso speaks to Ian Cronin, project lead...
Life transport Intricate supply chains have been a part of medical life for decades – but nowhere are they more complex than in the field of cell and gene therapy. Many treatments are...
Twisted system If you wanted to devise a test for how well pharma has optimised its logistics, you couldn’t do much better than asking the industry to build the supply chains for Covid-19...
Travel risk It’s not just shifting portfolios and expanding markets that supply chain strategies need to take into account. Our understanding of what constitutes an effective cold chain...
Vial bodies The global Covax initiative aims to produce two billion doses of Covid-19 vaccines by 2021 – without building any new factories. That’s going to take a lot of flexible,...
Black swan theory Covid-19 has ruthlessly exposed pharmaceutical supply chain issues, raising one huge question for companies and governments across Europe and North America: is it time to...
Development from home There’s nothing like a global pandemic for driving interest in remote drug development – but can computer-aided biology change how drugs are designed in the long term, or is it just...
Natural reaction There are 12 green chemistry principles. Using biocatalysis to synthesise pharmaceuticals fulfils the requirements of ten of them – with the other two not applicable. But...
Water solvable Pharmaceutical development is a delicate balance of stability, manufacturability and bioavailability. For all the advantages that lipid-based excipients (LBEs) bring to the...
Make it warp Given the rapid innovation in drug modalities and the jet engine that Covid-19 has strapped to concepts of patient-centred design and digital health, it looks increasingly unlikely...
A standardised approach Douglas Fiebig, PhD, senior partner of Trilogy Writing & Consulting, Frankfurt, Germany, discusses the challenges encountered when responding to medical writing RFIs.
A trial run What a difference a pandemic makes. Clinical trials that would previously have taken years to design and conduct have delivered results in under 12 months, and stages once...
Support systems For years, the patient-centric promise of the decentralised trial was little more than a utopian dream. But, with a global pandemic keeping people in their homes, 2020 brought the...
Get the gears turning The demand for comparator products in clinical trials is growing rapidly, but the sourcing models are uniquely susceptible to blockages in the supply chain. Jim Banks asks Steven...
View all features A-Z
